121 related articles for article (PubMed ID: 17671528)
1. The correlation between FHIT, P53 and MMR genes in human papillomavirus-associated cervical carcinoma.
Bahnassy AA; Zekri AR; Madbouly MS; El-Naggar M; El-Khelany ZF; El-Merzebany MM
J Egypt Natl Canc Inst; 2006 Sep; 18(3):191-202. PubMed ID: 17671528
[TBL] [Abstract][Full Text] [Related]
2. Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization.
Bai LX; Wang JT; Ding L; Jiang SW; Kang HJ; Gao CF; Chen X; Chen C; Zhou Q
Asian Pac J Cancer Prev; 2014; 15(21):9313-7. PubMed ID: 25422218
[TBL] [Abstract][Full Text] [Related]
3. FHIT alterations in cancerous and non-cancerous cervical epithelium.
Yoshino K; Enomoto T; Nakamura T; Sun H; Ozaki K; Nakashima R; Wada H; Saitoh J; Watanabe Y; Noda K; Murata Y
Int J Cancer; 2000 Jan; 85(1):6-13. PubMed ID: 10585575
[TBL] [Abstract][Full Text] [Related]
4. Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population.
Neyaz MK; Kumar RS; Hussain S; Naqvi SH; Kohaar I; Thakur N; Kashyap V; Das BC; Husain SA; Bharadwaj M
Biomarkers; 2008 Sep; 13(6):597-606. PubMed ID: 18608185
[TBL] [Abstract][Full Text] [Related]
5. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
[TBL] [Abstract][Full Text] [Related]
6. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
Wang J; Cheng YW; Wu DW; Chen JT; Chen CY; Chou MC; Lee H
Cancer Lett; 2006 Apr; 235(1):18-25. PubMed ID: 15935551
[TBL] [Abstract][Full Text] [Related]
7. Reduction in the copy number and expression level of the recurrent human papillomavirus integration gene fragile histidine triad (FHIT) predicts the transition of cervical lesions.
Wang L; Shen H; Feng B; Zhu D; Yu L; Tian X; Ren C; Gao C; Li X; Ma D; Hu Z; Wang H
PLoS One; 2017; 12(4):e0175520. PubMed ID: 28414756
[TBL] [Abstract][Full Text] [Related]
8. Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer.
Takizawa S; Nakagawa S; Nakagawa K; Yasugi T; Fujii T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Br J Cancer; 2003 Apr; 88(8):1213-6. PubMed ID: 12698186
[TBL] [Abstract][Full Text] [Related]
9. [Expression of FHIT genes in CIN and cervical carcinoma and the relationship between FHIT gene and p53 and HPV16/18].
Zhang WM; Shuai CX; Zheng FY; Huang YP; Wang QJ; Zhu-Hua ; He QX
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):452-5. PubMed ID: 17152494
[TBL] [Abstract][Full Text] [Related]
10. Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer.
Butler D; Collins C; Mabruk M; Leader MB; Kay EW
Gynecol Oncol; 2002 Aug; 86(2):144-9. PubMed ID: 12144820
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features.
Butler D; Collins C; Mabruk M; Barry Walsh C; Leader MB; Kay EW
J Pathol; 2000 Dec; 192(4):502-10. PubMed ID: 11113868
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FHIT transcripts in cervical and endometrial cancers.
Su TH; Wang JC; Tseng HH; Chang CP; Chang TA; Wei HJ; Chang JG
Int J Cancer; 1998 Apr; 76(2):216-22. PubMed ID: 9537583
[TBL] [Abstract][Full Text] [Related]
13. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
14. HPV-associated cervical cancers show frequent allelic loss at 3p14 but no apparent aberration of FHIT mRNA.
Chu TY; Shen CY; Chiou YS; Lu JJ; Perng CL; Yu MS; Liu HS
Int J Cancer; 1998 Jan; 75(2):199-204. PubMed ID: 9462708
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the FHIT gene in human colorectal cancer is independent of high-risk HPV infection.
Yu HG; Shun LB; Luo HS; Huang H; Yu BP; Yu JP; Meier JJ; Schrader H; Bastian A; Schmitz F; Schmidt WE
Int J Colorectal Dis; 2002 Nov; 17(6):396-401. PubMed ID: 12355215
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of hepatocellular carcinoma.
Zekri AR; Sabry GM; Bahnassy AA; Shalaby KA; Abdel-Wahabh SA; Zakaria S
World J Gastroenterol; 2005 May; 11(20):3020-6. PubMed ID: 15918183
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type.
Muller CY; O'Boyle JD; Fong KM; Wistuba II; Biesterveld E; Ahmadian M; Miller DS; Gazdar AF; Minna JD
J Natl Cancer Inst; 1998 Mar; 90(6):433-9. PubMed ID: 9521167
[TBL] [Abstract][Full Text] [Related]
18. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone.
Ishikawa H; Mitsuhashi N; Sakurai H; Maebayashi K; Niibe H
Cancer; 2001 Jan; 91(1):80-9. PubMed ID: 11148563
[TBL] [Abstract][Full Text] [Related]
19. Significance of combined detection of p53 and FHIT in cervical carcinoma diagnosis.
Du CX; Li SQ; Wang AH; Wang Y
Eur J Gynaecol Oncol; 2014; 35(3):298-300. PubMed ID: 24984545
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer.
Chava S; Mohan V; Shetty PJ; Manolla ML; Vaidya S; Khan IA; Waseem GL; Boddala P; Ahuja YR; Hasan Q
Dis Esophagus; 2012 Jan; 25(1):81-7. PubMed ID: 21668571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
